apatinib
1 clinical trial
6 products
4 abstracts
1 indication
Indication
Immunotherapy for Gastric CancerClinical trial
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: Randomized Control, Open, Multicenter Trial-2 (TAOS-3B-Trial-2)Status: Recruiting, Estimated PCD: 2025-03-01
Abstract
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of General Internal Medicine,
Abstract
Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,
Abstract
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.Org: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Radiology, Fudan University Shanghai Cancer Center, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital,
Product
pyrotinib + apatinibProduct
Camrelizumab + Apatinib